CN108245625A - A kind of hypoglycemic composition and preparation method thereof and purposes - Google Patents
A kind of hypoglycemic composition and preparation method thereof and purposes Download PDFInfo
- Publication number
- CN108245625A CN108245625A CN201611234676.2A CN201611234676A CN108245625A CN 108245625 A CN108245625 A CN 108245625A CN 201611234676 A CN201611234676 A CN 201611234676A CN 108245625 A CN108245625 A CN 108245625A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- highland barley
- composition
- sealwort
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 235000007340 Hordeum vulgare Nutrition 0.000 claims abstract description 61
- 239000000843 powder Substances 0.000 claims abstract description 60
- 241000209140 Triticum Species 0.000 claims abstract description 30
- 235000021307 Triticum Nutrition 0.000 claims abstract description 30
- 244000197580 Poria cocos Species 0.000 claims abstract description 29
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 29
- 229920001202 Inulin Polymers 0.000 claims abstract description 28
- 240000000249 Morus alba Species 0.000 claims abstract description 28
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 28
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 28
- 229940029339 inulin Drugs 0.000 claims abstract description 28
- 210000000582 semen Anatomy 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 241000209219 Hordeum Species 0.000 claims description 59
- 235000007319 Avena orientalis Nutrition 0.000 claims description 28
- 241000209763 Avena sativa Species 0.000 claims description 12
- 235000007558 Avena sp Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000015895 biscuits Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims 4
- 244000000231 Sesamum indicum Species 0.000 claims 3
- 241000207961 Sesamum Species 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 240000005979 Hordeum vulgare Species 0.000 abstract 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229910003978 SiClx Inorganic materials 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Present invention relates particularly to a kind of hypoglycemic composition and preparation method thereof and purposes.The raw material of the composition includes：5~40 parts by weight of highland barley wheat seedling powder, 5~40 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 6~28 parts by weight of inulin, 6~28 parts by weight of highland barley, 6~28 parts by weight of oat, 7~21 parts by weight of Poria cocos, 7~21 parts by weight of sealwort, 3~14 parts by weight of mulberry leaf powder, 3~14 parts by weight of Semen sesami nigrum.The present invention fully considers the composition of raw material and the mutual proportioning of each raw material, each raw material is made to cooperate under specific proportioning, collective effect, so as to play hypoglycemic effect；In addition, the composition not only has the function of significant hypoglycemic, but also toxic side effect is smaller, safety is higher, and composition is simple, cost is relatively low.
Description
Technical field
The invention belongs to drug, health products or field of food, and in particular to a kind of hypoglycemic composition and its preparation side
Method and purposes.
Background technology
In recent years, with the raising of people's daily life level and the increase of life stress, diabetes prevalence drastically on
It rises.If diabetes are not diagnosed in time and regular treatment, a variety of chronic complicating diseases can be caused.According to statistics, in diabetic
There are the concurrent blood vessel of more than 1/2 person and neuropathy, there are about 30% concurrent proliferative retinopathy, wherein 1-2% may be developed to
Blindness.
Chinese patent literature CN101554228A is disclosed：A kind of five-color hypoglycemic nutritional rice and processing method, raw material packet
It includes：Radix Codonopsis, ginseng, oat, Poria cocos, sealwort, Mulberry-leaf Tea, Semen sesami nigrum etc.；With edible and health care dual function, it is suitble to diabetes
Patient and hyperglycemia population are eaten.However, there is the shortcomings of composition is complicated, cost is higher in above-mentioned composition, so as to limit it
Using.
Therefore, study novel therapeutic effect is good, toxic side effect is small, composition is simple, it is lower-cost have hypoglycemic work
Composition is of great significance.
Invention content
Therefore, a kind of therapeutic effect of present invention offer is good, toxic side effect is small, composition is simple, lower-cost hypoglycemic
Composition, and then preparation method and purposes are provided.
In order to solve the above technical problems, the present invention is achieved through the following technical solutions：
The present invention provides a kind of hypoglycemic composition, and the raw material of the composition includes：
5~40 parts by weight of highland barley wheat seedling powder, 5~40 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 6~28 parts by weight of inulin, 6~28 weight of highland barley
Measure part, 6~28 parts by weight of oat, 7~21 parts by weight of Poria cocos, 7~21 parts by weight of sealwort, 3~14 parts by weight of mulberry leaf powder, Semen sesami nigrum
3~14 parts by weight.
Preferably, the above-mentioned hypoglycemic composition of the present invention, the raw material of the composition include：
10~30 parts by weight of highland barley wheat seedling powder, 10~30 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 10~20 parts by weight of inulin, highland barley 10~
20 parts by weight, 10~20 parts by weight of oat, 10~15 parts by weight of Poria cocos, 10~15 parts by weight of sealwort, 5~10 weight of mulberry leaf powder
Part, 5~10 parts by weight of Semen sesami nigrum.
It is further preferred that the above-mentioned hypoglycemic composition of the present invention, the raw material of the composition include：
20 parts by weight of highland barley wheat seedling powder, 19 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 22 parts by weight of inulin, 17 parts by weight of highland barley, oat 24
Parts by weight, 13 parts by weight of Poria cocos, 14 parts by weight of sealwort, 8 parts by weight of mulberry leaf powder, 6 parts by weight of Semen sesami nigrum；Or
10 parts by weight of highland barley wheat seedling powder, 30 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 10 parts by weight of inulin, 20 parts by weight of highland barley, oat 10
Parts by weight, 15 parts by weight of Poria cocos, 10 parts by weight of sealwort, 10 parts by weight of mulberry leaf powder, 5 parts by weight of Semen sesami nigrum；Or
30 parts by weight of highland barley wheat seedling powder, 10 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 20 parts by weight of inulin, 10 parts by weight of highland barley, oat 20
Parts by weight, 10 parts by weight of Poria cocos, 15 parts by weight of sealwort, 5 parts by weight of mulberry leaf powder, 10 parts by weight of Semen sesami nigrum；Or
17 parts by weight of highland barley wheat seedling powder, 23 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 18 parts by weight of inulin, 19 parts by weight of highland barley, oat 15
Parts by weight, 12 parts by weight of Poria cocos, 15 parts by weight of sealwort, 5 parts by weight of mulberry leaf powder, 6 parts by weight of Semen sesami nigrum.
It is further preferred that the above-mentioned hypoglycemic composition of the present invention, the highland barley wheat seedling powder is according to following preparation method
It is prepared：
The highland barley seedling of non-jointing is taken, is cleaned, 1~2h is dried at 60~100 DEG C, then ultramicro grinding to 200~1000
Mesh to get.
It is further preferred that the above-mentioned hypoglycemic composition of the present invention, the highland barley wheat seedling powder is according to following preparation method
It is prepared：
Take the highland barley seedling of non-jointing, clean, 1.5h is dried at 80 DEG C, then ultramicro grinding to 200~600 mesh to get.
The present invention also provides a kind of preparation methods of above-mentioned hypoglycemic composition, include the following steps：
Highland barley wheat seedling powder, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, the mulberry leaf powder of selected parts by weight are taken respectively
And Semen sesami nigrum, crush, be uniformly mixed, heated at 40~300 DEG C 0.5~3 hour to get.
Preferably, the preparation method of the above-mentioned hypoglycemic composition of the present invention,
Highland barley wheat seedling powder, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, the mulberry leaf powder of selected parts by weight are taken respectively
And Semen sesami nigrum, crush, be uniformly mixed, heated at 60~250 DEG C 1~2.5 hour to get.
It is further preferred that the preparation method of the above-mentioned hypoglycemic composition of the present invention,
Highland barley wheat seedling powder, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, the mulberry leaf powder of selected parts by weight are taken respectively
And Semen sesami nigrum, crush, be uniformly mixed, heated at 100~200 DEG C 1~1.5 hour to get.
It is prepared the present invention also provides the preparation including above-mentioned hypoglycemic composition or including above-mentioned preparation method
Composition preparation.
The composition adds in customary adjuvant, according to common process, be made clinically acceptable tablet, capsule, dissipate
Agent, mixture, pill, granule, solution, syrup, soft extract, beverage, biscuit, candy or cake.
The customary adjuvant is：Filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, corrigent, anti-corrosion
Agent, matrix etc..Filler includes：Starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；It collapses
Solution agent includes：Starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low substitution hydroxyl
Third cellulose, cross-linked carboxymethyl cellulose are received；Lubricant includes：Magnesium stearate, lauryl sodium sulfate, talcum powder, dioxy
SiClx etc.；Suspending agent includes：Polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Bonding
Agent includes, starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；Sweetener includes：Saccharin sodium, aspartame, sugarcane
Sugar, honey element, enoxolone etc.；Corrigent includes：Sweetener and various essence；Preservative includes：Parabens, benzoic acid,
Sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc.；Matrix includes：PEG6000、
PEG4000, insect wax etc..
The present invention also provides the systems of above-mentioned composition, the composition that above-mentioned preparation method is prepared or above-mentioned composition
Application of the agent in the drug with hypoglycemic effect, health products or food is prepared.
Technical scheme of the present invention has the following advantages that：
(1) composition of the present invention fully considers the composition of raw material and the mutual proportioning of each raw material, makes each raw material
It cooperates under specific proportioning, collective effect, so as to play hypoglycemic effect；
(2) composition of the present invention, not only has the function of significant hypoglycemic, but also toxic side effect is smaller, safety
Property is higher；
(3) composition of the present invention, only including 9 kinds of raw materials, composition is simple, cost is relatively low.
Specific embodiment
In following embodiment and experimental example, (1) highland barley wheat seedling powder is prepared according to following preparation method：Take non-jointing
Highland barley seedling, cleaning, 1.5h is dried at 80 DEG C, then ultramicro grinding to 400~800 mesh to get；(2) seed of Radix Et Rhizoma Fagopyri Tatarici, inulin,
Highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and Semen sesami nigrum are commercially available product.
Embodiment 1
The raw material of the hypoglycemic composition of the present embodiment forms：
Highland barley wheat seedling powder 20g, seed of Radix Et Rhizoma Fagopyri Tatarici 19g, inulin 22g, highland barley 17g, oat 24g, Poria cocos 13g, sealwort 14g, mulberry
Leaf powder 8g, Semen sesami nigrum 6g；
The preparation method of the composition, includes the following steps：
Take respectively the highland barley wheat seedling powder of selected weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and
Semen sesami nigrum, crush, be uniformly mixed, heated at 60~250 DEG C 1~2.5 hour to get.
The hypoglycemic composition of the present embodiment adds in customary adjuvant, and according to common process, tablet is made.
Embodiment 2
The raw material of the hypoglycemic composition of the present embodiment forms：
Highland barley wheat seedling powder 10g, seed of Radix Et Rhizoma Fagopyri Tatarici 30g, inulin 10g, highland barley 20g, oat 10g, Poria cocos 15g, sealwort 10g, mulberry
Leaf powder 10g, Semen sesami nigrum 5g；
The preparation method of the composition, includes the following steps：
Take respectively the highland barley wheat seedling powder of selected weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and
Semen sesami nigrum, crush, be uniformly mixed, heated at 60~250 DEG C 1~2.5 hour to get.
The hypoglycemic composition of the present embodiment adds in customary adjuvant, and according to common process, capsule is made.
Embodiment 3
The raw material of the hypoglycemic composition of the present embodiment forms：
Highland barley wheat seedling powder 30g, seed of Radix Et Rhizoma Fagopyri Tatarici 10g, inulin 20g, highland barley 10g, oat 20g, Poria cocos 10g, sealwort 15g, mulberry
Leaf powder 5g, Semen sesami nigrum 10g；
The preparation method of the composition, includes the following steps：
Take respectively the highland barley wheat seedling powder of selected weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and
Semen sesami nigrum, crush, be uniformly mixed, heated at 60~250 DEG C 1~2.5 hour to get.
The hypoglycemic composition of the present embodiment adds in customary adjuvant, and according to common process, granule is made.
Embodiment 4
The raw material of the hypoglycemic composition of the present embodiment forms：
Highland barley wheat seedling powder 17g, seed of Radix Et Rhizoma Fagopyri Tatarici 23g, inulin 18g, highland barley 19g, oat 15g, Poria cocos 12g, sealwort 15g, mulberry
Leaf powder 5g, Semen sesami nigrum 6g；
The preparation method of the composition, includes the following steps：
Take respectively the highland barley wheat seedling powder of selected weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and
Semen sesami nigrum, crush, be uniformly mixed, heated at 60~250 DEG C 1~2.5 hour to get.
The hypoglycemic composition of the present embodiment adds in customary adjuvant, and according to common process, powder is made.
Experimental example 1
1st, experiment purpose
Study the hypoglycemic effect of the composition of the present invention.
2nd, experimental method
The hyperglycemic patients of 200 6.1~6.9mmol/L of fasting blood-glucose are selected, exclude following patient：(1) with pernicious
Disease, such as tumour, severe cardiac, liver, kidney diaseases；Thyroid disease；(2) experiment starts once to take hypoglycemic or lipid-loweringing in first 3 months
Drug.
During the experiment, subject keep diet and living habit unlimited as possible, it is impossible to take hypoglycemic or fat-reducing medicament.
Above-mentioned 200 subjects are randomly divided into experimental group 1-4 groups and blank control group, every group 40.
Experimental group 1-4 groups take the composition 10g of embodiment 1-4 preparations respectively daily, and blank control group takes peace daily
Console agent 10g；Each group is continuously taken 2 months, 3 times a day.Remaining time of each group not dietary restriction, does not change lifestyles.
This experiment is combined the effect of evaluation each group using counter point between patient's Self-control method and group.
Before the experiment with experiment at the end of, each group detects following biochemical indicator：Fasting blood-glucose, HbAle egg
In vain, insulin, insulin resistance index, oral glucose tolerance test (OTGG) detection 0min, 30min, 60min, 90min
With the blood glucose of 120min.
The variation of any biochemical indicator of own control is denoted as effectively more than 1% before and after patient's experiment, is denoted as more than 5% aobvious
Effect, it is invalid to be denoted as less than 1%.
3rd, experimental result
The results are shown in Table 1 for the specific experiment of each group.
The specific experiment result of the hypoglycemic experiment of 1 each group of table
| Group | Number of cases | Effective number of cases | Effective number of cases | Invalid number of cases | Total effective rate (%) |
| Blank control group | 40 | 0 | 6 | 34 | 15.0 |
| 1 group of experimental group | 40 | 7 | 28 | 5 | 87.5 |
| 2 groups of experimental group | 40 | 6 | 26 | 8 | 80.0 |
| 3 groups of experimental group | 40 | 8 | 25 | 7 | 82.5 |
| 4 groups of experimental group | 40 | 10 | 24 | 6 | 85.0 |
As shown in Table 1：Compared with blank control group, the hypoglycemic effect of experimental group 1-4 groups is more notable.
4th, experiment conclusion
The composition of the present invention has significant hypoglycemic effect.
Obviously, the above embodiments are merely examples for clarifying the description, and is not intended to limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And the obvious variation thus extended out or
Among changing still in the protection domain of the invention.
Claims (8)
1. a kind of hypoglycemic composition, which is characterized in that the raw material of the composition includes：
5~40 parts by weight of highland barley wheat seedling powder, 5~40 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 6~28 parts by weight of inulin, 6~28 weight of highland barley
Part, 6~28 parts by weight of oat, 7~21 parts by weight of Poria cocos, 7~21 parts by weight of sealwort, 3~14 parts by weight of mulberry leaf powder, Semen sesami nigrum 3
~14 parts by weight.
2. hypoglycemic composition according to claim 1, which is characterized in that the raw material of the composition includes：
10~30 parts by weight of highland barley wheat seedling powder, 10~30 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 10~20 parts by weight of inulin, 10~20 weight of highland barley
Measure part, 10~20 parts by weight of oat, 10~15 parts by weight of Poria cocos, 10~15 parts by weight of sealwort, 5~10 parts by weight of mulberry leaf powder, black
5~10 parts by weight of sesame.
3. hypoglycemic composition according to claim 2, which is characterized in that the raw material of the composition includes：
20 parts by weight of highland barley wheat seedling powder, 19 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 22 parts by weight of inulin, 17 parts by weight of highland barley, 24 weight of oat
Part, 13 parts by weight of Poria cocos, 14 parts by weight of sealwort, 8 parts by weight of mulberry leaf powder, 6 parts by weight of Semen sesami nigrum；Or
10 parts by weight of highland barley wheat seedling powder, 30 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 10 parts by weight of inulin, 20 parts by weight of highland barley, 10 weight of oat
Part, 15 parts by weight of Poria cocos, 10 parts by weight of sealwort, 10 parts by weight of mulberry leaf powder, 5 parts by weight of Semen sesami nigrum；Or
30 parts by weight of highland barley wheat seedling powder, 10 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 20 parts by weight of inulin, 10 parts by weight of highland barley, 20 weight of oat
Part, 10 parts by weight of Poria cocos, 15 parts by weight of sealwort, 5 parts by weight of mulberry leaf powder, 10 parts by weight of Semen sesami nigrum；Or
17 parts by weight of highland barley wheat seedling powder, 23 parts by weight of seed of Radix Et Rhizoma Fagopyri Tatarici, 18 parts by weight of inulin, 19 parts by weight of highland barley, 15 weight of oat
Part, 12 parts by weight of Poria cocos, 15 parts by weight of sealwort, 5 parts by weight of mulberry leaf powder, 6 parts by weight of Semen sesami nigrum.
4. the preparation method of the hypoglycemic composition of a kind of claim 1-3 any one of them, which is characterized in that including following
Step：
The highland barley wheat seedling powders of selected parts by weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and black are taken respectively
Sesame, crush, be uniformly mixed, heated at 40~300 DEG C 0.5~3 hour to get.
5. the preparation method of hypoglycemic composition according to claim 4, which is characterized in that
The highland barley wheat seedling powders of selected parts by weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and black are taken respectively
Sesame, crush, be uniformly mixed, heated at 60~250 DEG C 1~2.5 hour to get.
6. the preparation method of hypoglycemic composition according to claim 5, which is characterized in that
The highland barley wheat seedling powders of selected parts by weight, seed of Radix Et Rhizoma Fagopyri Tatarici, inulin, highland barley, oat, Poria cocos, sealwort, mulberry leaf powder and black are taken respectively
Sesame, crush, be uniformly mixed, heated at 100~200 DEG C 1~1.5 hour to get.
7. preparation including the hypoglycemic composition of claim 1-3 any one of them or any including claim 4-6
The preparation of composition that preparation method described in is prepared, which is characterized in that
The composition adds in customary adjuvant, and according to common process, clinically acceptable tablet, capsule, powder, conjunction is made
Agent, pill, granule, solution, syrup, soft extract, beverage, biscuit, candy or cake.
8. claim 1-3 any one of them composition, claim 4-6 any one of them preparation methods are prepared
The preparation of composition described in composition or claim 7 is in the drug with hypoglycemic effect, health products or food is prepared
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611234676.2A CN108245625A (en) | 2016-12-28 | 2016-12-28 | A kind of hypoglycemic composition and preparation method thereof and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611234676.2A CN108245625A (en) | 2016-12-28 | 2016-12-28 | A kind of hypoglycemic composition and preparation method thereof and purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108245625A true CN108245625A (en) | 2018-07-06 |
Family
ID=62719970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611234676.2A Pending CN108245625A (en) | 2016-12-28 | 2016-12-28 | A kind of hypoglycemic composition and preparation method thereof and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108245625A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430341A (en) * | 2018-10-25 | 2019-03-08 | 成都喜上天宝电子商务有限公司 | A kind of instant food and its production technology suitable for diabetic patients |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564161A (en) * | 2009-02-25 | 2009-10-28 | 田向东 | Nutrition health food special for patients with hyperlipemia and hyperglycemia and preparation method thereof |
| CN103169090A (en) * | 2011-12-22 | 2013-06-26 | 上海颐养堂食品科技有限公司 | Synthetic rice suitable for patients with diabetes mellitus and preparation method thereof |
| CN103238897A (en) * | 2013-05-02 | 2013-08-14 | 广州施健生物科技有限公司 | Composite plant solid drink suitable for diabetic patients |
| CN103478576A (en) * | 2013-08-30 | 2014-01-01 | 兴化市联富食品有限公司 | Five-wheat seedlings series products and production method thereof |
| CN103564581A (en) * | 2012-07-28 | 2014-02-12 | 白立民 | Special beverage for hyperglycaemia and diabetes mellitus patients |
| CN103564335A (en) * | 2012-07-28 | 2014-02-12 | 英勇来 | Special baked cake for diabetes mellitus and hyperglycaemia patients |
-
2016
- 2016-12-28 CN CN201611234676.2A patent/CN108245625A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564161A (en) * | 2009-02-25 | 2009-10-28 | 田向东 | Nutrition health food special for patients with hyperlipemia and hyperglycemia and preparation method thereof |
| CN103169090A (en) * | 2011-12-22 | 2013-06-26 | 上海颐养堂食品科技有限公司 | Synthetic rice suitable for patients with diabetes mellitus and preparation method thereof |
| CN103564581A (en) * | 2012-07-28 | 2014-02-12 | 白立民 | Special beverage for hyperglycaemia and diabetes mellitus patients |
| CN103564335A (en) * | 2012-07-28 | 2014-02-12 | 英勇来 | Special baked cake for diabetes mellitus and hyperglycaemia patients |
| CN103238897A (en) * | 2013-05-02 | 2013-08-14 | 广州施健生物科技有限公司 | Composite plant solid drink suitable for diabetic patients |
| CN103478576A (en) * | 2013-08-30 | 2014-01-01 | 兴化市联富食品有限公司 | Five-wheat seedlings series products and production method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王慧芳等: "药食两用中药降血糖作用研究进展 ", 《中国煤炭工业医学杂志》 * |
| 王慧芳等: "药食两用中药降血糖作用研究进展", 《中国煤炭工业医学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109430341A (en) * | 2018-10-25 | 2019-03-08 | 成都喜上天宝电子商务有限公司 | A kind of instant food and its production technology suitable for diabetic patients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9603866B2 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN101595993B (en) | Health-care food | |
| CN105250789A (en) | Hypoglycemic plant fermentation preparation and preparation method thereof | |
| CN101589812B (en) | Health-care food | |
| CN1813819B (en) | Hedgehog hydnum fruiting body or hyphostroma, culture extract, formulation and preparing method | |
| CN108245553A (en) | A kind of hypoglycemic composition and preparation method thereof and purposes | |
| CN108245625A (en) | A kind of hypoglycemic composition and preparation method thereof and purposes | |
| TWI725317B (en) | Use of composition of neoandrographolide in lowering blood sugar | |
| CN110960502A (en) | Substance for treating metabolic syndrome and application thereof | |
| US20220047658A1 (en) | Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications | |
| CN107693555A (en) | A kind of medicine and purposes for treating diabetes | |
| CN107853712A (en) | A kind of composition for alleviating hyperglycaemia and preparation method thereof and purposes | |
| CN102793798B (en) | Medicinal composition for auxiliary treatment of diabetic coronary artery disease | |
| CN107261079B (en) | Application of longhurendan in preparation of medicine for preventing and/or treating diabetes | |
| CN111729058A (en) | Traditional Chinese medicine composition for invigorating spleen and eliminating turbid pathogen and application thereof | |
| WO2019228210A1 (en) | Pharmaceutical use of composition comprising radix astragali, radix puerariae, and herba erigerontis | |
| CN108421020A (en) | It is a kind of to be used to treat Ginger P.E of diabetic retinopathy and its preparation method and application | |
| CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN108261511A (en) | A kind of composition with antiobesity action and preparation method thereof and purposes | |
| CN104758772A (en) | Japanese galangal flower extract for improving sugar tolerance and usage of Japanese galangal flower extract | |
| CN107029092A (en) | A kind of mare's milk sugar-reduction traditional Chinese medicine composition and its preparation method and application | |
| CN107898788A (en) | A kind of hypoglycemic pharmaceutical composition and preparation method thereof | |
| CN103432089A (en) | Metformin hydrochloride chewable tablet and preparation method thereof | |
| CN114748567B (en) | Hypoglycemic composition containing antrodia camphorata and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180706 |
|
| RJ01 | Rejection of invention patent application after publication |